contained total gingerol and shogaol concentrations that were similar to the analyzed dietary supplement.
Conclusion
Of the twenty commercially available ginger products examined, those with the highest content of active, antiemetic constituents were the standardized ginger extracts and supplements although ginger spices also showed high levels of active constituents per serve. In addition, standard deviation reveals a large variation within each product type.
Introduction
The rhizome of ginger (Zingiber officinale) contains many bioactive compounds. The gingerol class of compounds is the primary bioactive agent within the non-volatile, pungent component of ginger. Shogaols are the degradation product of gingerols. These are present in low concentrations in fresh ginger but increase when gingerols are exposed to heat, acid or other conditions which allow the alkene to form (an elimination product) (Bhattarai et al., 2001 ). The shogaols and gingerols are differentiated by the presence of either an aliphatic hydroxyl group, beta to the carbonyl (gingerols) or elimination of the hydroxyl group to form a double bond (shogaols) on the alpha carbon to the aliphatic carbonyl. supplements, information regarding the potency of available ginger preparations will also be of interest to healthcare professionals seeking these products for their adjuvant medicinal properties to determine their potential to produce side effects and interactions. Due to the differing biological activity of the gingerol and shogaol compounds, it is also prudent to measure the concentration of each of these individual compounds within commonly consumed ginger products.
The aim of this study was to determine the concentration of the primary bioactive compounds within an expanded range of commercially available ginger products, including dietary supplements and ginger-containing drinks and food products using Reverse Phase-High Performance Liquid Chromatography (RP-HPLC). Using the results of this analysis, the clinical and research implications of the therapeutic use of ginger products will be discussed.
Methods

Chemicals and Materials
HPLC-grade water, methanol, ethyl acetate, and acetonitrile were purchased from ThermoFisher (Massachusetts, USA) and Sigma Aldrich (Missouri, USA). [6] [10] -shogaol standards were purchased from Chromadex (Irvine, CA, U.S.A). Ginger products were purchased from one local supermarket (Gold Coast, Australia) and one online store (based in New Zealand) in April, 2014. In addition, one supplement was supplied by the respective manufacturer for use in this study. In total, 20 products were purchased, including dietary supplements, beverages, spices (ground ginger), teas, and confectionery.
Sample preparation
Due to the variety of types of ginger products analyzed, two extraction protocols were required.
All samples were prepared in triplicate. Percentage yield was determined by conducting each extraction protocol with a 0.08 mg/mL standard mix.
Ethyl acetate extraction
In order to analyze the ginger supplements, biscuit, and spices, ethyl acetate (10mL) was added to 500mg samples of spices, pierced supplements or crushed biscuit.
Samples were vortexed then sonicated for 30 minutes using a CamLab TransSonic T310 sonicator. Samples were centrifuged (20 minutes at 2500rpm and 25 degrees Celsius) using a Beckman Coulter Allegra X-15R centrifuge. The supernatant was subjected to second pass extraction using an additional ethyl acetate (10 mL). The supernatants of both extractions from each product were combined and evaporated to dryness. The samples were reconstituted in methanol (1.5mL) and stored at 4ºC.
Serving sizes for the supplements and biscuit were in accordance with suggested serving sizes by the manufacturer. The serving size for the spices was set at 0.2 gram.
Liquid/liquid extraction
Beverage samples (50mL, degassed) and confectionery samples (500mg) were diluted in HPLC water (15mL). For the tea products, three tea bags were infused in HPLC-grade water (50mL, room temperature) for three minutes. All samples were left overnight and then extracted in ethyl acetate (10mL). A second pass extraction was conducted. The supernatants of both extractions from each product were combined and evaporated to dryness. The samples were reconstituted in methanol (1.5mL) and stored at 4ºC.
The serving size of the beverages was set at 250mL and confectionery serving size was defined as 5g, as this was found to be the approximate weight of a single piece of confectionery.
Standard preparation
Stock solutions (10mL) of each standard were prepared from the 5mg material supplied by the manufacturer Chromadex (Irvine, CA, U.S.A). A dilution series of the standard mix were prepared as needed between 0.50 ug/mL to 200 ug/mL. Working standards were prepared in the range of 0.0005 to 0.2 mg/mL and stored at 4ºC.
HPLC analysis
Ginger samples were separated on a Waters Alliance e-2695 Separations System RP-HPLC and detected with a 2489 Dual-Beam UV detector. A 150x4.6mm C-18 reversed phase column (Luna C18 5µM; Phenomenex, USA) was fitted with a guard column. The limit of detection (LoD) was determined using the standard deviation of each component calibration curve and slope. The LoD was calculated as 3.3 times the ratio of standard deviation to slope for each component while the limit of quantitation (LoQ) was calculated as 10 x the ratio of standard deviation to slope for each component ( Table 1) .
The mean concentration of [6] When analyzed in terms of the approximate concentration that would be consumed in one recommended serve of each product, there were dietary supplements as well as some confectionery and beverage products, that contained large concentrations of the analyzed compounds. Ginger ales and confectionery are often recommended by health professionals to treat nausea. Currently, the smallest effective dose of ginger as well as the optimal form of ginger has not been elucidated and is an area that requires continued research to inform clinical practice. However, these results demonstrate that it is feasible to achieve an intake of the principle active compounds of ginger by consuming certain commercially available food products that is comparable to most dietary supplements analyzed in this study as well as effective doses used in previous clinical trials. For example, a large RCT (N=576) reported that two dosages of a standardized ginger extract, 0.5 and 1g/day, were effective in reducing chemotherapy-induced nausea and vomiting (Ryan et al., 2012) . The effective daily dose of gingerol and shogaol for each dosage was 17mg and 34mg, respectively. In our analysis, four confectionery and beverage products contained a total gingerol and shogaol concentration similar to the dosage used in previous studies and the dietary supplements included in the current analysis (Ryan et al., 2012) . Therefore, these results also suggest that it is indeed feasible to attain equivalent amounts of gingerol and shogaols used in previous clinical trials via dietary intake (Ryan et al., 2012) . This demonstrates the need for the consumption of ginger products to be monitored during future clinical trials investigating ginger because the consumption of additional ginger products is likely to influence the effective total intake of ginger compounds.
Furthermore, previous studies have demonstrated a potential ceiling effect with higher doses (2g) of ginger supplementation resulting in less or no control of symptoms compared to lower doses (Marx et al., 2013) . Thus, the consumption of additional ginger products could potentially increase the total consumption of active compounds in excess of a therapeutic dosage.
In addition, as previously noted by our group as well as other authors, the lack of analysis of ginger preparations and the lack of standardized extracts used in clinical trials could be responsible for the sometimes conflicting results reported due to the variability in active It should be noted that ginger contains a wide variety of bioactive compounds that have potentially beneficial properties (Chrubasik et al., 2005) . Therefore, while this study was able to determine the concentration of an expanded range of these principle compounds compared to previous studies, other potentially important ginger compounds were not able to be analyzed due to the lack of commercial standards. Investigation of the concentrations of other compounds such as zingibain and dehydroshogaols in commercial products is recommended in future studies as these compounds have also demonstrated biological activity relevant to chronic conditions (Chrubasik et al., 2005) . A second limitation of this study is that some of the samples used were purchased commercially from nearby stores. The concentration of compounds could have been influenced by factors such as storage conditions; therefore, the results of this analysis might not be representative of the product when stored in different conditions. There is also the possibility that there was a variation in the concentration of analyzed compounds between different batches of the same product, particularly if different batches are sourced from multiple locations. This study analyzed a single sample of each product and so future trials may benefit from analyzing multiple batches of the same product. Finally, due to the use of ethyl-acetate to extract the active compounds, our study provides limited data on the bioaccessability of the active compounds.
However, rather than to compare the bioaccessibilty of target analytes, the current study was designed to measure and compare the total composition of gingerols and shogaols in the included products. The bioaccessibilty of these compounds is an area of necessary research and future studies that resemble the human digestive process (e.g. by using an aqueous extraction) are required to improve the current literature.
In summary, using an expanded range of commercial ginger products, the inclusion of an additional active compound, and a protocol designed to reflect the concentration of active compounds likely to be consumed, the results and discussion of this study provide novel clinical and research recommendations regarding the therapeutic use of ginger products.
Conclusion
An analysis of 20 commercially available ginger products demonstrated wide variation in the total amount of gingerols and shogaols within different ginger products, with standardized ginger extracts and spices containing the largest concentration of compounds. Biscuits and teas contained the least concentrations of the relevant compounds. When calculated by serving, certain beverages and confectionery contained similar or greater concentrations of the analyzed compounds to the ginger supplements; hence, future clinical trials investigating ginger formulations should ensure that the consumption of other ginger products is monitored so as to not confound the study results. In addition, the inconsistent concentration of active compounds 
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